Location History:
- Neuilly/Seine, FR (2010)
- Neuilly sur Seine, FR (2020 - 2023)
Company Filing History:
5 out of 154 
4 out of 5,094 
3 out of 1,745 
Years Active: 2010-2025
Title: Genevieve Almouzni: Innovator in Engineered Immune Cells
Introduction
Genevieve Almouzni is a prominent inventor based in Neuilly sur Seine, France. She has made significant contributions to the field of immunology, particularly in the development of engineered immune cells. With a total of 5 patents, her work focuses on innovative approaches to cancer treatment.
Latest Patents
One of her latest patents involves immune cells defective for SUV39H1. This invention relates to an engineered immune cell that is specifically designed to be defective for Suv39h1. The engineered immune cell also includes a genetically engineered antigen receptor that binds to a target antigen. The method for obtaining this genetically engineered immune cell includes inhibiting the expression and/or activity of Suv39h1. Additionally, it may involve introducing a genetically engineered antigen receptor that specifically binds to a target antigen. This invention is particularly relevant for adoptive therapy, especially in the treatment of cancer.
Career Highlights
Genevieve Almouzni has worked with esteemed institutions such as Institut Curie and the Centre National de la Recherche Scientifique. Her research has significantly advanced the understanding of immune cell engineering and its applications in therapeutic settings.
Collaborations
Throughout her career, Almouzni has collaborated with notable colleagues, including Sebastian Amigorena and Eliane Piaggio. These collaborations have further enriched her research and contributions to the field.
Conclusion
Genevieve Almouzni's innovative work in engineered immune cells showcases her dedication to advancing cancer treatment. Her patents and collaborations reflect her significant impact on immunology and therapeutic development.